Literature DB >> 22773603

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.

Sarah Abu Kar1, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V Tiu, Bartlomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A Sekeres, Alan F List, Michael A McDevitt, Jaroslaw P Maciejewski.   

Abstract

Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelomonocytic leukemia and closely related diseases. We genotyped a cohort of patients with chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia for somatic mutations in U2AF1, SRSF2, SF3B1 and in the other 12 most frequently affected genes in these conditions. Chromosomal abnormalities were assessed by nucleotide polymorphism array-based karyotyping. The presence of molecular lesions was correlated with clinical endpoints. Mutations in SRSF2, U2AF1 and SF3B1 were found in 32%, 13% and 6% of cases of chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, respectively. Spliceosomal genes were affected in various combinations with other mutations, including TET2, ASXL1, CBL, EZH2, RAS, IDH1/2, DNMT3A, TP53, UTX and RUNX1. Worse overall survival was associated with mutations in U2AF1 (P=0.047) and DNMT3A (P=0.015). RAS mutations had an impact on overall survival in secondary acute myeloid leukemia (P=0.0456). By comparison, our screening of juvenile myelomonocytic leukemia cases showed mutations in ASXL1 (4%), CBL (10%), and RAS (6%) but not in IDH1/2, TET2, EZH2, DNMT3A or the three spliceosomal genes. SRSF2 and U2AF1 along with TET2 (48%) and ASXL1 (38%) are frequently affected by somatic mutations in chronic myelomonocytic leukemia, quite distinctly from the profile seen in juvenile myelomonocytic leukemia. Our data also suggest that spliceosomal mutations are of ancestral origin.

Entities:  

Mesh:

Year:  2012        PMID: 22773603      PMCID: PMC3533671          DOI: 10.3324/haematol.2012.064048

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Authors:  B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Authors:  Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.

Authors:  V Visconte; H Makishima; A Jankowska; H Szpurka; F Traina; A Jerez; C O'Keefe; H J Rogers; M A Sekeres; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

4.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

Authors:  Frank G Rücker; Richard F Schlenk; Lars Bullinger; Sabine Kayser; Veronica Teleanu; Helena Kett; Marianne Habdank; Carla-Maria Kugler; Karlheinz Holzmann; Verena I Gaidzik; Peter Paschka; Gerhard Held; Marie von Lilienfeld-Toal; Michael Lübbert; Stefan Fröhling; Thorsten Zenz; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Peter Lichter; Konstanze Döhner; Hartmut Döhner
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

5.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.

Authors:  Víctor Quesada; Laura Conde; Neus Villamor; Gonzalo R Ordóñez; Pedro Jares; Laia Bassaganyas; Andrew J Ramsay; Sílvia Beà; Magda Pinyol; Alejandra Martínez-Trillos; Mónica López-Guerra; Dolors Colomer; Alba Navarro; Tycho Baumann; Marta Aymerich; María Rozman; Julio Delgado; Eva Giné; Jesús M Hernández; Marcos González-Díaz; Diana A Puente; Gloria Velasco; José M P Freije; José M C Tubío; Romina Royo; Josep L Gelpí; Modesto Orozco; David G Pisano; Jorge Zamora; Miguel Vázquez; Alfonso Valencia; Heinz Himmelbauer; Mónica Bayés; Simon Heath; Marta Gut; Ivo Gut; Xavier Estivill; Armando López-Guillermo; Xose S Puente; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

6.  Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.

Authors:  Shinsuke Hirabayashi; Christian Flotho; Jessica Moetter; Michael Heuser; Henrik Hasle; Bernd Gruhn; Thomas Klingebiel; Felicitas Thol; Brigitte Schlegelberger; Irith Baumann; Brigitte Strahm; Jan Stary; Franco Locatelli; Marco Zecca; Eva Bergstraesser; Michael Dworzak; Marry M van den Heuvel-Eibrink; Barbara De Moerloose; Seishi Ogawa; Charlotte M Niemeyer; Marcin W Wlodarski
Journal:  Blood       Date:  2012-01-11       Impact factor: 22.113

Review 7.  Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.

Authors:  Ulrike Bacher; Torsten Haferlach; Susanne Schnittger; Hans Kreipe; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2011-03-09       Impact factor: 6.998

8.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Authors:  Mrinal M Patnaik; Terra L Lasho; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Guillermo Garcia-Manero; David P Steensma; Animesh Pardanani; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

9.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.

Authors:  Hideki Makishima; Valeria Visconte; Hirotoshi Sakaguchi; Anna M Jankowska; Sarah Abu Kar; Andres Jerez; Bartlomiej Przychodzen; Manoj Bupathi; Kathryn Guinta; Manuel G Afable; Mikkael A Sekeres; Richard A Padgett; Ramon V Tiu; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-02-09       Impact factor: 22.113

10.  Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Authors:  Timothy A Graubert; Dong Shen; Li Ding; Theresa Okeyo-Owuor; Cara L Lunn; Jin Shao; Kilannin Krysiak; Christopher C Harris; Daniel C Koboldt; David E Larson; Michael D McLellan; David J Dooling; Rachel M Abbott; Robert S Fulton; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Marcus Grillot; Jack Baty; Sharon Heath; John L Frater; Talat Nasim; Daniel C Link; Michael H Tomasson; Peter Westervelt; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Matthew J Walter
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

View more
  34 in total

Review 1.  Defects in spliceosomal machinery: a new pathway of leukaemogenesis.

Authors:  Jaroslaw P Maciejewski; Richard A Padgett
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

Review 2.  Examining the impact of gene variants on histone lysine methylation.

Authors:  Capucine Van Rechem; Johnathan R Whetstine
Journal:  Biochim Biophys Acta       Date:  2014-05-23

Review 3.  Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.

Authors:  Charlotte K Brierley; David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

4.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

5.  BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

Authors:  Liping Zhang; Rajesh R Singh; Keyur P Patel; Francesco Stingo; Mark Routbort; M James You; Roberto N Miranda; Guillermo Garcia-Manero; Hagop M Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Joseph D Khoury
Journal:  Am J Hematol       Date:  2014-02-10       Impact factor: 10.047

Review 6.  Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age.

Authors:  Jaroslaw P Maciejewski; Suresh K Balasubramanian
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Authors:  Katia Hanssens; Fabienne Brenet; Julie Agopian; Sophie Georgin-Lavialle; Gandhi Damaj; Laure Cabaret; Maria Olivia Chandesris; Paulo de Sepulveda; Olivier Hermine; Patrice Dubreuil; Erinn Soucie
Journal:  Haematologica       Date:  2014-01-03       Impact factor: 9.941

8.  Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.

Authors:  Jia Gu; Zhiqiong Wang; Min Xiao; Xia Mao; Li Zhu; Ying Wang; Wei Huang
Journal:  Cancer Biol Ther       Date:  2017-01-19       Impact factor: 4.742

9.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.

Authors:  Bartlomiej Przychodzen; Andres Jerez; Kathryn Guinta; Mikkael A Sekeres; Richard Padgett; Jaroslaw P Maciejewski; Hideki Makishima
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.